In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please cancel claims 29 and 30 without prejudice to their presentation in another application, amend claims 19 and 26, and add new claims 33-36 as follows:

1-11. (canceled).

12. (previously presented) A composition comprising a peptide consisting of the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1), in which the peptide is conjugated to a carrier protein.

13. (canceled).

14. (previously presented) A method of treating cancer comprising:

administering to a subject in need thereof a therapeutically effective amount of a monoclonal antibody, or a fragment thereof, that binds to a peptide;

wherein the peptide comprises the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1).

15-17. (canceled).

18. (previously presented) The method of claim 14 wherein the monoclonal antibody is humanized.

19. (currently amended) A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a monoclonal antibody, or a fragment thereof, that binds to a peptide, ~~The method of claim 14~~ wherein the monoclonal antibody is 6313/G2 produced by the hybridoma cell line designated by accession number 93072117.

20. (previously presented) The method of claim 14 wherein the cancer is prostate cancer or breast cancer.

21. (previously presented) A method of treating a disease or condition associated with vascular smooth muscle cell proliferation comprising:

administering to a subject in need thereof a therapeutically effective amount of a monoclonal antibody, or a fragment thereof, that binds to a peptide;

wherein the peptide comprises the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1).

22-24. (canceled).

25. (previously presented) The method of claim 21 wherein the monoclonal antibody is humanized.

26. (currently amended) A method of treating a disease or condition associated with vascular smooth muscle cell proliferation comprising administering to a subject in need thereof a therapeutically effective amount of a monoclonal antibody, or a fragment thereof, that binds to a peptide, ~~The method of claim 21~~ wherein the monoclonal antibody is 6313/G2 produced by the hybridoma cell line designated by accession number 93072117.

27. (previously presented) The method of claim 21 wherein the disease or condition is atherosclerosis.

28. (previously presented) The composition of claim 12 further comprising an adjuvant.

29-30. (canceled).

31. (previously presented) The method of claim 14 wherein the antibody fragment is a Fab, $F(ab')_2$, Fv, or scFv fragment.

32. (previously presented) The method of claim 21 wherein the antibody fragment is a Fab, $F(ab')_2$, Fv, or scFv fragment.

33. (new) A method of treating cancer comprising:

administering to a subject in need thereof a therapeutically effective amount of a monoclonal antibody, or a fragment thereof, that binds to a peptide;

wherein the peptide consists of the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1) or the sequence EDGIKRIQDD (SEQ ID NO:2), or a conservative substitution of either.

34. (new) The method of claim 33 wherein the following residues may each independently be as follows: residue 8 may be glutamic acid, aspartic acid, or glutamine, residue 9 may be aspartic acid or glutamic acid, residue 10 may be glycine or alanine, residue 11 may be isoleucine or alanine, residue 12 may be lysine or arginine, residue 13 may be arginine or lysine, residue 14 may be isoleucine or alanine, residue 15 may be glutamine or asparagine, and residues 16 and 17 may each either be aspartic acid or glutamic acid, wherein residue numbers refer to SEQ ID NO:1.

35. (new) A method of treating a disease or condition associated with vascular smooth muscle cell proliferation comprising:

administering to a subject in need thereof a therapeutically effective amount of a monoclonal antibody, or a fragment thereof, that binds to a peptide;

wherein the peptide consists of the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1) or the sequence EDGIKRIQDD (SEQ ID NO:2), or a conservative substitution of either.

36. (new) The method of claim 35 wherein the following residues may each independently be as follows: residue 8 may be glutamic acid, aspartic acid, or glutamine, residue 9 may be aspartic acid or glutamic acid, residue 10 may be glycine or alanine, residue 11 may be isoleucine or alanine, residue 12 may be lysine or arginine, residue 13 may be arginine or lysine,

residue 14 may be isoleucine or alanine, residue 15 may be glutamine or asparagine, and residues 16 and 17 may each either be aspartic acid or glutamic acid, wherein residue numbers refer to SEQ ID NO:1.